Functional association of the N-terminal residues with the central region in glucagon-related peptides

Journal of Peptide Science

Volumn 17, Issue 10, 2011, Pages 659-666

  Patterson, James T ^a   Day, Jonathan W ^a,b   Gelfanov, Vasily M ^a   Dimarchi, Richard D ^a  

^a INDIANA UNIVERSITY   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

CGCR; Co agonist; DPP IV; Ex 4; GLP 1; GLP 1R; Glucagon

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUTAMIC ACID; GLYCINE;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ARTICLE; ENZYME STABILITY; PRIORITY JOURNAL; PROTEIN CLEAVAGE;

AMINO ACID SEQUENCE; ANIMALS; DIPEPTIDYL PEPTIDASE 4; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDES; HUMANS; PEPTIDES; RECEPTORS, GLUCAGON; SEQUENCE HOMOLOGY, AMINO ACID; VENOMS;

EID: 80053187244     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.1385     Document Type: Article

References (48)

1. Vilsboll T, Holst JJ. Incretins, insulin secretion and Type 2 diabetes mellitus. Diabetologia 2004; 47(3): 357-366.
2. Drucker DJ. The biology of incretin hormones. Cell Metab. 2006; 3(3): 153-165.
3. Oshima I, Hirota M, Ohboshi C, Shima K. Comparison of half-disappearance times, distribution volumes and metabolic clearance rates of exogenous glucagon-like peptide 1 and glucagon in rats. Regul. Pept. 1988; 21(1-2): 85-93.
4. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur. J. Biochem. 1993; 214(3): 829-835.
5. Kieffer TJ, McIntosh CH, Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995; 136(8): 3585-3596.
6. Hassan M, Eskilsson A, Nilsson C, Jonsson C, Jacobsson H, Refai E, Larsson S, Efendic S. In vivo dynamic distribution of 131I-glucagon-like peptide-1 (7-36) amide in the rat studied by gamma camera. Nucl. Med. Biol. 1999; 26(4): 413-420.
7. Holst JJ, Orskov C. The incretin approach for diabetes treatment: modulation of islet hormone release by GLP-1 agonism. Diabetes 2004; 53(Suppl. 3): S197-204.
8. Kruger DF, Bode B, Spollett GR. Understanding GLP-1 analogs and enhancing patients success. Diab. Educ. 2010; 36(Suppl. 3): 44S-72S; quiz 73S-74S.
9. Hui H, Zhao X, Perfetti R. Structure and function studies of glucagon-like peptide-1 (GLP-1): the designing of a novel pharmacological agent for the treatment of diabetes. Diab. Metab. Res. Rev. 2005; 21(4): 313-331.
10. Greig NH, Holloway HW, De Ore KA, Jani D, Wang Y, Zhou J, Garant MJ, Egan JM. Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations. Diabetologia 1999; 42(1): 45-50.
11. Skovgaard M, Kodra JT, Gram DX, Knudsen SM, Madsen D, Liberles DA. Using evolutionary information and ancestral sequences to understand the sequence-function relationship in GLP-1 agonists. J. Mol. Biol. 2006; 363(5): 977-988.
12. Young AA, Gedulin BR, Bhavsar S, Bodkin N, Jodka C, Hansen B, Denaro M. Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 1999; 48(5): 1026-1034.
13. Goke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, Goke B. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J. Biol. Chem. 1993; 268(26): 19650-19655.
14. Al-Sabah S, Donnelly D. A model for receptor-peptide binding at the glucagon-like peptide-1 (GLP-1) receptor through the analysis of truncated ligands and receptors. Br. J. Pharmacol. 2003; 140(2): 339-346.
15. Burcelin R, Dolci W, Thorens B. Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analog of glucagon-like peptide-1. Metabolism 1999; 48(2): 252-258.
16. Doyle ME, Theodorakis MJ, Holloway HW, Bernier M, Greig NH, Egan JM. The importance of the nine-amino acid C-terminal sequence of exendin-4 for binding to the GLP-1 receptor and for biological activity. Regul. Pept. 2003; 114(2-3): 153-158.
17. Deacon CF, Knudsen LB, Madsen K, Wiberg FC, Jacobsen O, Holst JJ. Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity. Diabetologia 1998; 41(3): 271-278.
18. Siegel EG, Gallwitz B, Scharf G, Mentlein R, Morys-Wortmann C, Folsch UR, Schrezenmeir J, Drescher K, Schmidt WE. Biological activity of GLP-1-analogues with N-terminal modifications. Regul. Pept. 1999; 79(2-3): 93-102.
19. Xiao Q, Giguere J, Parisien M, Jeng W, St-Pierre SA, Brubaker PL, Wheeler MB. Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo. Biochemistry 2001; 40(9): 2860-2869.
20. Sarrauste de Menthiere C, Chavanieu A, Grassy G, Dalle S, Salazar G, Kervran A, Pfeiffer B, Renard P, Delagrange P, Manechez D, Bakes D, Ktorza A, Calas B. Structural requirements of the N-terminal region of GLP-1-(7-37)-NH2 for receptor interaction and cAMP production. Eur. J. Med. Chem. 2004; 39(6): 473-480.
21. Adelhorst K, Hedegaard BB, Knudsen LB, Kirk O. Structure-activity studies of glucagon-like peptide-1. J. Biol. Chem. 1994; 269(9): 6275-6278.
22. Hareter A, Hoffmann E, Bode HP, Goke B, Goke R. The positive charge of the imidazole side chain of histidine7 is crucial for GLP-1 action. Endocrinol. J. 1997; 44(5): 701-705.
23. Gallwitz B, Witt M, Paetzold G, Morys-Wortmann C, Zimmermann B, Eckart K, Folsch UR, Schmidt WE. Structure/activity characterization of glucagon-like peptide-1. Eur. J. Biochem. 1994; 225(3): 1151-1156.
24. Patterson JT, Ottaway N, Gelfanov VM, Smiley DL, Perez-Tilve D, Pfluger PT, Tschop MH, Dimarchi RD. A novel human-based receptor antagonist of sustained action reveals body weight control by endogenous GLP-1. ACS Chem. Biol. 2011; 6(2): 135-145.
25. Andersen NH, Brodsky Y, Neidigh JW, Prickett KS. Medium-dependence of the secondary structure of exendin-4 and glucagon-like-peptide-1. Bioorg. Med. Chem. 2002; 10(1): 79-85.
26. Thornton K, Gorenstein DG. Structure of glucagon-like peptide (7-36) amide in a dodecylphosphocholine micelle as determined by 2D NMR. Biochemistry 1994; 33(12): 3532-3539.
27. Neidigh JW, Fesinmeyer RM, Prickett KS, Andersen NH. Exendin-4 and glucagon-like-peptide-1: NMR structural comparisons in the solution and micelle-associated states. Biochemistry 2001; 40(44): 13188-13200.
28. Chang X, Keller D, O'Donoghue SI, Led JJ. NMR studies of the aggregation of glucagon-like peptide-1: formation of a symmetric helical dimer. FEBS Lett. 2002; 515(1-3): 165-170.
29. Neidigh JW, Andersen NH. Peptide conformational changes induced by tryptophan-phosphocholine interactions in a micelle. Biopolymers 2002; 65(5): 354-361.
30. Runge S, Schimmer S, Oschmann J, Schiodt CB, Knudsen SM, Jeppesen CB, Madsen K, Lau J, Thogersen H, Rudolph R. Differential structural properties of GLP-1 and exendin-4 determine their relative affinity for the GLP-1 receptor N-terminal extracellular domain. Biochemistry 2007; 46(19): 5830-5840.
31. Schnolzer M, Alewood P, Jones A, Alewood D, Kent SB. In situ neutralization in Boc-chemistry solid phase peptide synthesis. Rapid, high yield assembly of difficult sequences. Int. J. Pept. Protein Res. 1992; 40(3-4): 180-193.
32. Miranda LP, Winters KA, Gegg CV, Patel A, Aral J, Long J, Zhang J, Diamond S, Guido M, Stanislaus S, Ma M, Li H, Rose MJ, Poppe L, Veniant MM. Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo activity. J. Med. Chem. 2008; 51(9): 2758-2765.
33. Day JW, Ottaway N, Patterson JT, Gelfanov V, Smiley D, Gidda J, Findeisen H, Bruemmer D, Drucker DJ, Chaudhary N, Holland J, Hembree J, Abplanalp W, Grant E, Ruehl J, Wilson H, Kirchner H, Lockie SH, Hofmann S, Woods SC, Nogueiras R, Pfluger PT, Perez-Tilve D, DiMarchi R, Tschop MH. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat. Chem. Biol. 2009; 5(10): 749-757.
34. Runge S, Thogersen H, Madsen K, Lau J, Rudolph R. Crystal structure of the ligand-bound glucagon-like peptide-1 receptor extracellular domain. J. Biol. Chem. 2008; 283(17): 11340-11347.
35. Underwood CR, Garibay P, Knudsen LB, Hastrup S, Peters GH, Rudolph R, Reedtz-Runge S. Crystal structure of glucagon-like peptide-1 in complex with the extracellular domain of the glucagon-like peptide-1 receptor. J. Biol. Chem. 2010; 285(1): 723-730.
36. Murage EN, Gao G, Bisello A, Ahn JM. Development of potent glucagon-like peptide-1 agonists with high enzyme stability via introduction of multiple lactam bridges. J. Med. Chem. 2010; 53(17): 6412-6420.
37. Day JW, Li P, Patterson JT, Chabenne J, Chabenne MD, Gelfanov VM, Dimarchi RD. Charge inversion at position 68 of the glucagon and glucagon-like peptide-1 receptors supports selectivity in hormone action. J. Pept. Sci. 2011; 17(3): 218-225.
38. Hjorth SA, Adelhorst K, Pedersen BB, Kirk O, Schwartz TW. Glucagon and glucagon-like peptide 1: selective receptor recognition via distinct peptide epitopes. J. Biol. Chem. 1994; 269(48): 30121-30124.
39. Runge S, Gram C, Brauner-Osborne H, Madsen K, Knudsen LB, Wulff BS. Three distinct epitopes on the extracellular face of the glucagon receptor determine specificity for the glucagon amino terminus. J. Biol. Chem. 2003; 278(30): 28005-28010.
40. Runge S, Wulff BS, Madsen K, Brauner-Osborne H, Knudsen LB. Different domains of the glucagon and glucagon-like peptide-1 receptors provide the critical determinants of ligand selectivity. Br. J. Pharmacol. 2003; 138(5): 787-794.
41. Pan CQ, Buxton JM, Yung SL, Tom I, Yang L, Chen H, MacDougall M, Bell A, Claus TH, Clairmont KB, Whelan JP. Design of a long acting peptide functioning as both a glucagon-like peptide-1 receptor agonist and a glucagon receptor antagonist. J. Biol. Chem. 2006; 281(18): 12506-12515.
42. Gardella TJ, Luck MD, Fan MH, Lee C. Transmembrane residues of the parathyroid hormone (PTH)/PTH-related peptide receptor that specifically affect binding and signaling by agonist ligands. J. Biol. Chem. 1996; 271(22): 12820-12825.
43. Lopez de Maturana R, Donnelly D. The glucagon-like peptide-1 receptor binding site for the N-terminus of GLP-1 requires polarity at Asp198 rather than negative charge. FEBS Lett. 2002; 530(1-3): 244-248.
44. Lin F, Wang R. Molecular modeling of the three-dimensional structure of GLP-1R and its interactions with several agonists. J. Mol. Model 2009; 15(1): 53-65.
45. Unson CG. Molecular determinants of glucagon receptor signaling. Biopolymers 2002; 66(4): 218-235.
46. Parthier C, Reedtz-Runge S, Rudolph R, Stubbs MT. Passing the baton in class B GPCRs: peptide hormone activation via helix induction? Trends Biochem. Sci. 2009; 34(6): 303-310.
47. Wittelsberger A, Corich M, Thomas BE, Lee BK, Barazza A, Czodrowski P, Mierke DF, Chorev M, Rosenblatt M. The mid-region of parathyroid hormone (1-34) serves as a functional docking domain in receptor activation. Biochemistry 2006; 45(7): 2027-2034.
48. Shimizu M, Shimizu N, Tsang JC, Petroni BD, Khatri A, Potts JT Jr, Gardella TJ. Residue 19 of the parathyroid hormone (PTH) modulates ligand interaction with the juxtamembrane region of the PTH-1 receptor. Biochemistry 2002; 41(44): 13224-13233.